Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Global Blood Therapeutics, Inc. (NASDAQ: GBT).

Full DD Report for GBT

You must become a subscriber to view this report.


Recent News from (NASDAQ: GBT)

Global Blood Therapeutics, Voxelotor in Advanced Clinicals, Analysts Review and Target
NEW YORK, NY / ACCESSWIRE / December 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Global Blood Therapeutics , Inc. (NASDAQ: GBT) , a clinical-stage bioph...
Source: ACCESSWIRE IA
Date: December, 10 2018 08:15
Global Blood Therapeutics: Can The Rally Continue?
"In chaos, there is fertility. " - Anais Nin Today, we revisit Global Blood Therapeutics ( GBT ) . This stock has had an up and down year as can be seen from the chart below. The shares have recently been on an upswing despite the current horrid sentiment in the market. The company jus...
Source: SeekingAlpha
Date: December, 08 2018 02:44
Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Global Blood Therapeutics
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial Average jumped 1.13 percent to close at 25,826.43, while the S&P 500 Index inc...
Source: ACCESSWIRE IA
Date: December, 04 2018 08:00
Global Blood's voxelotor shows positive action in late-stage sickle cell study; shares up 56%
Global Blood Therapeutics ( GBT +55.7% ) is up on more than an 8x surge in volume on the heels of positive data from a Phase 3 clinical trial, HOPE , evaluating voxelotor in patients at least 12 years old with sickle cell disease (SCD). The results were presented at ASH in San Diego. ...
Source: SeekingAlpha
Date: December, 03 2018 12:53
Healthcare and Industrial goods dominate midday movers
More news on: Tesaro, Global Blood Therapeutics, Atossa Genetics, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: December, 03 2018 12:46
GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile
Interim Analysis of Data from 1500 mg Cohort of HOPE-KIDS 1 Study Consistent with Phase 3 HOPE- Results in Demonstrating Improvement in Hemoglobin and Clinical Measures of Hemolysis and Favorable Safety in Pediatric Patients Company to Host Investor Webcast Today, Monday, December 3, ...
Source: GlobeNewswire
Date: December, 03 2018 10:00
VIPS, BZUN among premarket gainers
Tesaro (NASDAQ: TSRO ) +59%  on acquisition by Glaxo for $75. More news on: Tesaro, Global Blood Therapeutics, Hudson Technologies, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: December, 03 2018 09:25
FDA accepts GBT's proposal for accelerated approval pathway for Voxelotor; shares up 42% premarket
FDA agrees with Global Blood Therapeutics' (NASDAQ: GBT ) proposal relating to use of an accelerated approval pathway for voxelotor for the treatment of sickle cell disease (SCD). More news on: Global Blood Therapeutics, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: December, 03 2018 08:51
GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
Pre-NDA Meeting to be Requested for First Quarter of 2019 Company to Host Conference Call and Webcast Today, Monday, December 3, at 5:30 a.m. PT/8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT) today a...
Source: GlobeNewswire
Date: December, 03 2018 08:00
GBT to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Provide a Regulatory Update for Voxelotor
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the company will host a conference call to provide a regulatory update for voxelotor tomorrow, Monday, December 3, 2018, at 8:30 a.m. ET...
Source: GlobeNewswire
Date: December, 02 2018 19:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0845.3044.6045.651943.95595,349
2018-05-1748.2548.1048.6547.30647,993
2018-02-2663.6062.5063.8562.10414,889
2018-02-2363.5562.8563.6061.3774538,161
2018-02-2262.3562.6565.0561.50810,032

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-12112,414198,93956.5068Short
2018-12-11116,269182,87663.5781Short
2018-12-10146,141312,50046.7651Short
2018-12-07568,5011,089,04552.2018Short
2018-12-06390,703621,03862.9113Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GBT.


About Global Blood Therapeutics, Inc. (NASDAQ: GBT)

Logo for Global Blood Therapeutics, Inc. (NASDAQ: GBT)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $2,287,302,430 - 05/16/2018
  • Issue and Outstanding: 51,825,849 - 04/30/2018

 


Recent Filings from (NASDAQ: GBT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 07 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 12 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018

 

 


Daily Technical Chart for (NASDAQ: GBT)

Daily Technical Chart for (NASDAQ: GBT)


Stay tuned for daily updates and more on (NASDAQ: GBT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GBT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GBT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GBT and does not buy, sell, or trade any shares of GBT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/